Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.
暂无分享,去创建一个
[1] Paul Greengard,et al. Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.
[2] Ronald H. Schwartz,et al. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process , 2003, Nature Immunology.
[3] A. Wells,et al. Opposing Roles for the Cyclin-Dependent Kinase Inhibitor p27kip1 in the Control of CD4+ T Cell Proliferation and Effector Function1 , 2005, The Journal of Immunology.
[4] R. Schwartz,et al. Multifactor cis-dominant negative regulation of IL-2 gene expression in anergized T cells. , 1996, Journal of immunology.
[5] Chyung-Ru Wang,et al. Helper T cell differentiation is controlled by the cell cycle. , 1998, Immunity.
[6] Y. Iwamoto,et al. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance , 2006, Nature Immunology.
[7] B. Freedman,et al. Regulation of T Cell Activation and Tolerance by Phospholipase Cγ-1-Dependent Integrin Avidity Modulation1 , 2003, The Journal of Immunology.
[8] D. Franklin,et al. An Important Role of CDK Inhibitor p18INK4c in Modulating Antigen Receptor-Mediated T Cell Proliferation1 , 2001, The Journal of Immunology.
[9] A. Wells,et al. The role of cyclin-dependent kinases in T-cell development, proliferation, and function. , 2006, Critical reviews in immunology.
[10] James M. Roberts,et al. Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.
[11] M. Jenkins,et al. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. , 1991, Journal of immunology.
[12] M. Serrano,et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development , 2000, Nature Medicine.
[13] D. Mueller,et al. Evidence for repression of IL-2 gene activation in anergic T cells. , 1999, Journal of immunology.
[14] A. Wells,et al. Signals from CD28 Induce Stable Epigenetic Modification of the IL-2 Promoter1 , 2005, The Journal of Immunology.
[15] G. Nabel,et al. Regulation of NF-κB by Cyclin-Dependent Kinases Associated with the p300 Coactivator , 1997, Science.
[16] A. Senderowicz. Targeting cell cycle and apoptosis for the treatment of human malignancies. , 2004, Current opinion in cell biology.
[17] D. Mueller. E3 ubiquitin ligases as T cell anergy factors , 2004, Nature Immunology.
[18] R. Schwartz. T cell anergy. , 2003, Annual review of immunology.
[19] P. Fields,et al. Blocked Ras Activation in Anergic CD4+ T Cells , 1996, Science.
[20] K. Wood,et al. Regulatory lymphocytes: Regulatory T cells in transplantation tolerance , 2003, Nature Reviews Immunology.
[21] Fang Liu,et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads , 2004, Nature.
[22] R. Schwartz,et al. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. , 1999, Journal of immunology.
[23] B. Verdoodt,et al. The cyclin‐dependent kinase inhibitors p27Kip1 and p21Cip1 are not essential in T cell anergy , 2003, European journal of immunology.
[24] E. Palmer,et al. Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question1 , 2001, The Journal of Immunology.
[25] A. Senderowicz. Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials , 2003, Cancer biology & therapy.
[26] A. Wells. T-Cell Costimulatory Pathways Relevant to Transplant Rejection and Tolerance , 2002 .
[27] J. Gribben,et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. , 1994, Science.
[28] J. Gribben,et al. Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation , 1996, The Journal of experimental medicine.
[29] M. Croft,et al. Deficiency of the Cyclin Kinase Inhibitor p21(WAF-1/CIP-1) Promotes Apoptosis of Activated/Memory T Cells and Inhibits Spontaneous Systemic Autoimmunity , 2004, The Journal of experimental medicine.
[30] Kenneth M. Murphy,et al. Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.
[31] V. D’Agati,et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. , 2004, Journal of the American Society of Nephrology : JASN.
[32] Nikolai Zhelev,et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) , 2002, International journal of cancer.
[33] J. Gribben,et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[34] L. Turka,et al. T Cell Effector Function and Anergy Avoidance Are Quantitatively Linked to Cell Division1 , 2000, The Journal of Immunology.
[35] J. Ikeda,et al. Cyclin-dependent kinases as a therapeutic target for stroke. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] A. Mondino,et al. Blocked Signal Transduction to the ERK and JNK Protein Kinases in Anergic CD4+ T Cells , 1996, Science.
[37] P. Allen,et al. Selective activation of the calcium signaling pathway by altered peptide ligands , 1996, The Journal of experimental medicine.
[38] A. Khoruts,et al. Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness1 , 2001, The Journal of Immunology.
[39] Brian D. Dynlacht,et al. Regulation of transcription by proteins that control the cell cycle , 1997, Nature.
[40] S. Ely,et al. Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[41] A. Wells,et al. The Cyclin-Dependent Kinase Inhibitor p27kip1 Is Required for Transplantation Tolerance Induced by Costimulatory Blockade1 , 2006, The Journal of Immunology.
[42] Christopher Haslett,et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis , 2006, Nature Medicine.
[43] H. Gudmundsdottir,et al. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. , 1999, Journal of immunology.
[44] K. Gilbert,et al. The ability of antigen, but not interleukin‐2, to promote n‐butyrate‐induced T helper 1 cell anergy is associated with increased expression and altered association patterns of cyclin‐dependent kinase inhibitors , 2002, Immunology.
[45] K. Gilbert,et al. Induction of Anergy in Th1 Cells Associated with Increased Levels of Cyclin-Dependent Kinase Inhibitors p21Cip1 and p27Kip1 1 , 2001, The Journal of Immunology.
[46] P. Linsley,et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.
[47] Laurie A. Smith,et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine , 2006, Nature.
[48] P. Hodgkin,et al. Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[49] J. Allison,et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.
[50] T. Ushijima,et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory , 2006, The EMBO journal.
[51] R. Schwartz,et al. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. , 1992, International immunology.
[52] S. Ely,et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. , 2002, Immunity.
[53] D. Kono,et al. Role of Cyclin Kinase Inhibitor p21 in Systemic Autoimmunity1 2 , 2001, The Journal of Immunology.
[54] R. Schwartz,et al. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. , 1999, Journal of immunology.
[55] G. Freeman,et al. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. , 1997, Science.
[56] H. Gudmundsdottir,et al. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.
[57] W. Feeser,et al. Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways , 1996, The Journal of experimental medicine.
[58] J. Bluestone,et al. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. , 2001, The Journal of clinical investigation.
[59] Chou-Chi H. Li,et al. Association of Cdk2/Cyclin E and NF-κB Complexes at G1/S Phase , 1998 .
[60] P. Linsley,et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.
[61] G. Freeman,et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes , 2000, Nature Medicine.
[62] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[63] J. Powell. The induction and maintenance of T cell anergy. , 2006, Clinical immunology.
[64] Anjana Rao,et al. Transcriptional Mechanisms Underlying Lymphocyte Tolerance , 2002, Cell.
[65] J. Harbour,et al. The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.